Amylyx Pharmaceuticals, Inc. (AMLX) intrinsic value & 10-year financials
Amylyx Pharmaceuticals, Inc. (AMLX) has a Graham intrinsic value of $23.25 per share. At $26.34 on Oct 17, 2026, the stock trades 13% above that value. Over the last 6 fiscal years revenue grew 574.3% a year to $0, with an average return on invested capital of -67.0%.
- Graham intrinsic value
- $23.25
- Share price (Oct 17, 2026)
- $26.34
- Price vs Graham value
- 13% above
- Market cap
- $2.5B
- Revenue (FY2025)
- $0
- Revenue growth (6-yr CAGR)
- 574.3%
- ROIC (10-yr avg)
- -67.0%
- Free cash flow (FY2025)
- -$123.5M
AMLX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$144.7M | -$1.53 | -$123.5M | — | -179.1% |
| FY2024 | $87.4M | -$301.7M | -$4.43 | -$167.8M | -360.2% | -178.1% |
| FY2023 | $380.8M | $49.3M | $0.70 | $10.7M | 10.2% | 12.9% |
| FY2022 | $22.2M | -$198.4M | -$3.39 | -$182.4M | -905.7% | -71.3% |
| FY2021 | $285.0K | -$87.9M | -$1.48 | -$75.2M | -29013.3% | 80.7% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Amylyx Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Amylyx Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -15.5% ROIC.
Amylyx Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Amylyx Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $23.25 per share.